Pulmonary rehabilitation 2007: From bench to practice and back

Clinical and Investigative Medicine

Volumn 31, Issue 5, 2008, Pages

  Decramer, Marc ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CHRONIC OBSTRUCTIVE LUNG DISEASE; CONFERENCE PAPER; MUSCLE DISEASE; MUSCLE WEAKNESS; PRIORITY JOURNAL; PULMONARY REHABILITATION;

ANIMALS; CYTOKINES; HUMANS; INFLAMMATION; MUSCLE, SKELETAL; MUSCULAR DISEASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 52949140207     PISSN: 0147958X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (52)

1. Buist AS, Vollmer WM, Sullivan SD et al. The Burden of Obstructive Lung Disease Initiative (BOLD): rationale and design. COPD 2005;2:277-83.
2. GOLD Steering Committee. www.goldcopd.com. update 2006 2007.
3. Burrows B, Earle RH. Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N Engl J Med 1969;2808:397-404.
4. Decramer M, Gosselink R, Rutten-Van Molken M et al. Assessment of progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax 2005;60:335-42.
5. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002;166:675-9.
6. Calverley PM, Anderson JA, Celli B et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-89.
7. Decramer M, Celli B, Tashkin DP et al. Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: the UPLIFT trial. COPD 2004; 1:303-12.
8. Anzueto A, Tashkin D, Menjoge S et al. One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005;18:75-81.
9. Sin DD, Anthonisen NR, Soriano JB et al. Mortality in COPD: Role of comorbidities. Eur Respir J 2006;28:1245-57.
10. Sevenoaks MJ, Stockley RA. Chronic Obstructive Pulmonary Disease, inflammation and co-morbidity - a common inflammatory phenotype? Respir Res 2006;7:70.
11. Mapel DW, Hurley JS, Frost FJ et al. Health care utilization in chronic obstructive pulmonary disease. A case-control study in a health maintenance organization. Arch Intern Med 2000;160:2653-8.
12. Sorlie PD, Kannel WB, O'Connor G. Mortality associated with respiratory function and symptoms in advanced age. The Framingham Study. Am Rev Respir Dis 1989;140:379-84.
13. Sin DD, Wu L, Man SF. The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. Chest 2005;127:1952-9.
14. Mannino DM, Aguayo SM, Petty TL et al. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003;163:1475-80.
15. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:770-7.
16. Gosselink R, Troosters T, Decramer M. Peripheral muscle weakness contributes to exercise limitation in COPD. Am J Respir Crit Care Med 1996;153:976-80.
17. Engelen MP, Schols AM, Lamers RJ et al. Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease. Clin Nutr 1999;18:275-80.
18. Antonelli Inc, Fuso L, De Rosa M et al. Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J 1997;10:2794-800.
19. Marquis K, Maltais F, Duguay V et al. The metabolic syndrome in patients with chronic obstructive pulmonary disease. J Cardiopulm Rehabil 2005;25:226-32.
20. Mannino DM, Gagnon RC, Petty TL et al. Obstructive lung disease and low lung function in adults in the United States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000;160:1683-9.
21. Sin DD, Man JP, Man SF. The risk of osteoporosis in Caucasian men and women with obstructive airways disease. Am J Med 2003;114:10-4.
22. Bolton CE, Ionescu AA, Shiels KM et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:1286-93.
23. Kim HF, Kunik ME, Molinari VA et al. Functional impairment in COPD patients: the impact of anxiety and depression. Psychosomatics 2000;41:465-71.
24. Rochester DF, Braun NM. Determinants of maximal inspiratory pressure in chronic obstructive pulmonary disease. Am Rev Respir Dis 1985;132:42-7.
25. Maltais F, LeBlanc P, Jobin J et al. Peripheral muscle dysfunction in chronic obstructive pulmonary disease. Clin Chest Med 2000;21:665-77.
26. Farkas GA, Roussos C. Diaphragm in emphysematous hamsters: sarcomere adaptability. J Appl Physiol 1983;54:1635-40.
27. Similowski T, Yan S, Gauthier AP et al. Contractile properties of the human diaphragm during chronic hyperinflation. N Engl J Med 1991;325:917-23.
28. Spruit MA, Gosselink R, Troosters T et al. Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax 2003;58:752-6.
29. Couillard A, Maltais F, Saey D et al. Exercise-induced quadriceps oxidative stress and peripheral muscle dysfunction in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;167:1664-9.
30. Mancini DM, Henson D, LaManca J et al. Respiratory muscle function and dyspnea in patients with chronic congestive heart failure. Circulation 1992;86:909-18.
31. Stassijns G, Gayan-Ramirez G, De Leyn P et al. Systolic ventricular dysfunction causes selective diaphragm atrophy in rats. Am J Respir Crit Care Med 1998;158:1963-7.
32. Decramer M, Stas KJ. Corticosteroid-induced myopathy involving respiratory muscles in patients with chronic obstructive pulmonary disease or asthma. Am Rev Respir Dis 1992;146:800-2.
33. Decramer M, Lacquet LM, Fagard R et al. Corticosteroids contribute to muscle weakness in chronic airflow obstruction. Am J Respir Crit Care Med 1994;150:11-6.
34. Aubier M, Murciano D, Lecocguic Y et al. Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure. N Engl J Med 1985;313:420-4.
35. Pitta F, Troosters T, Spruit MA et al. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;171:972-7.
36. Pitta F, Troosters T, Probst VS et al. Physical activity and hospitalization for exacerbation of COPD. Chest 2006;129:536-44.
37. Janssen SP. Effects of cytokines on ventilatory and peripheral muscles. (PhD thesis). 2006.
38. Janssen SP, Gayan-Ramirez G, Van den BA et al. Interleukin-6 causes myocardial failure and skeletal muscle atrophy in rats. Circulation 2005;111:996-1005.
39. Greiwe JS, Cheng B, Rubin DC et al. Resistance exercise decreases skeletal muscle tumor necrosis factor alpha in frail elderly humans. FASEB J 2001;15:475-82.
40. Crul T, Spruit MA, Gayan-Ramirez G, Quarck R, Gosselink R, Troosters T, Pitta F, Decramer M. Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. Eur J Clin Invest 2007; 37: 897-904.
41. Hamilton AL, Killian KJ, Summers E et al. Muscle strength, symptom intensity, and exercise capacity in patients with cardiorespiratory disorders. Am J Respir Crit Care Med 1995;152(6 Pt 1):2021-31
42. Saey D, Debigare R, LeBlanc P et al. Contractile leg fatigue after cycle exercise: a factor limiting exercise in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003;168:425-30.
43. Decramer M, Gosselink R, Troosters T et al. Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J 1997;10:417-23.
44. Marquis K, Debigare R, Lacasse Y et al. Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002;166:809-13.
45. Troosters T, Casaburi R, Gosselink R et al. Pulmonary rehabilitation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005;172:19-38.
46. Troosters T, Gosselink R, Decramer M. Exercise training in COPD: how to distinguish responders from non-responders. J Cardiopulm Rehabil 2001;21:10-7.
47. Creutzberg EC, Wouters EF, Mostert R et al. A role for anabolic steroids in the rehabilitation of patients with COPD? A double-blind, placebo-controlled, randomized trial. Chest 2003;124:1733-42
48. Casaburi R, Bhasin S, Cosentino L et al. Effects of testosterone and resistance training in men with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170:870-8.
49. Emtner M, Porszasz J, Burns M et al. Benefits of supplemental oxygen in exercise training in nonhypoxemic chronic obstructive pulmonary disease patients. Am J Respir Crit Care Med 2003;168:1034-42.
50. Hawkins P, Johnson LC, Nikoletou D et al. Proportional assist ventilation as an aid to exercise training in severe chronic obstructive pulmonary disease. Thorax 2002;57:853-9.
51. Bourjeily-Habr G, Rochester CL, Palermo F et al. Randomised controlled trial of transcutaneous electrical muscle stimulation of the lower extremities in patients with chronic obstructive pulmonary disease. Thorax 2002;57:1045-9.
52. Neder JA, Sword D, Ward SA et al. Home based neuromuscular electrical stimulation as a new rehabilitative strategy for severely disabled patients with chronic obstructive pulmonary disease (COPD). Thorax 2002;57:333-7.